{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T01:39:01Z","timestamp":1759541941438,"version":"3.41.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2003,3,28]],"date-time":"2003-03-28T00:00:00Z","timestamp":1048809600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2003,5]]},"DOI":"10.1007\/s00228-003-0576-4","type":"journal-article","created":{"date-parts":[[2016,11,12]],"date-time":"2016-11-12T18:49:42Z","timestamp":1478976582000},"page":"45-50","source":"Crossref","is-referenced-by-count":45,"title":["Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype"],"prefix":"10.1007","volume":"59","author":[{"given":"Roland","family":"Berecz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfredo","family":"de la Rubia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro","family":"Dorado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro","family":"Fern\u00e1ndez-Salguero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marja-Liisa","family":"Dahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adri\u00e1n","family":"LLerena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2003,3,28]]},"reference":[{"key":"0576_CR1","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.3109\/00498259309059422","volume":"23","author":"Lin","year":"1993","unstructured":"Lin G, Hawes EM, McKay G, Korchinski ED, Midha KK (1993) Metabolism of piperidine-type phenothiazine antipsychotic agents. IV. Thioridazine in dog, man and rat. Xenobiotica 23:1059\u20131074","journal-title":"Xenobiotica"},{"key":"0576_CR2","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/S0022-3565(25)21626-3","volume":"231","author":"Kilts","year":"1984","unstructured":"Kilts CD, Knight DL, Mailman RB, Widerlov E, Breese GR (1984) Effects of thioridazine and its metabolites on dopaminergic function: drug metabolism as a determinant of the antidopaminergic actions of thioridazine. J Pharmacol Exp Ther 231:334\u2013342","journal-title":"J Pharmacol Exp Ther"},{"key":"0576_CR3","doi-asserted-by":"crossref","first-page":"11825","DOI":"10.1073\/pnas.90.24.11825","volume":"90","author":"Johansson","year":"1993","unstructured":"Johansson I, Lundqvist E, Bertilsson L, Dahl ML, Sj\u00f6qvist F, Ingelman-Sundberg M (1993) Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA 90:11825\u201311829","journal-title":"Proc Natl Acad Sci USA"},{"key":"0576_CR4","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0022-3565(25)10669-1","volume":"274","author":"Dahl","year":"1995","unstructured":"Dahl ML, Johansson I, Bertilsson L, Ingelman-Sundberg M, Sj\u00f6qvist F (1995) Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J Pharmacol Exp Ther 274:516\u2013520","journal-title":"J Pharmacol Exp Ther"},{"key":"0576_CR5","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/0009-9236(95)90151-5","volume":"57","author":"Ag\u00c3\u00bandez","year":"1995","unstructured":"Ag\u00fandez JA, Ledesma MC, Ladero JM, Ben\u00edtez J (1995) Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population. Clin Pharmacol Ther 57:265\u2013269","journal-title":"Clin Pharmacol Ther"},{"key":"0576_CR6","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1097\/00008571-199910000-00013","volume":"9","author":"Bernal","year":"1999","unstructured":"Bernal ML, Sinues B, Johansson I, McLellan RA, Wennerholm A, Dahl ML, Ingelman-Sundberg M, Bertilsson L (1999) Ten percent of North Spanish individuals carry duplicated or triplicated CYP2D6 genes associated with ultrarapid metabolism of debrisoquine. Pharmacogenetics 9:657\u2013660","journal-title":"Pharmacogenetics"},{"key":"0576_CR7","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/BF03190261","volume":"21","author":"LLerena","year":"1996","unstructured":"LLerena A, Cobaleda J, Mart\u00ednez C, Ben\u00edtez J (1996) Interethnic differences in drug metabolism: influence of sex-related and environmental factors on debrisoquine hydroxylation phenotype. Eur J Drug Metab Pharmacokinet 21:129\u2013138","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"0576_CR8","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/clpt.1991.22","volume":"49","author":"Bahr","year":"1991","unstructured":"Bahr C von, Movin G, Nordin C, Liden A, Hammarlund-Udenaes M, Hedberg A, Ring H, Sj\u00f6qvist F (1991) Plasma levels of thioridazine and metabolites are influenced by the debrisoquine hydroxylation phenotype. Clin Pharmacol Ther 49:234\u2013240","journal-title":"Clin Pharmacol Ther"},{"key":"0576_CR9","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/S0009-9236(96)80010-5","volume":"59","author":"Eap","year":"1996","unstructured":"Eap CB, Guenter TW, Sch\u00e4ublin-Loidl M, Stabl M, Koeb L, Powell K, Baumann P (1996) Plasma level of the enantiomers of thioridazine, thioridazine 2-sulfoxide, thioridazine 2-sulfone, and thioridazine 5-sulfoxide in poor and extensive metabolizers of dextrometorphan and mephenytoin. Clin Pharmacol Ther 59:322\u2013331","journal-title":"Clin Pharmacol Ther"},{"key":"0576_CR10","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1016\/0006-2952(85)90533-7","volume":"34","author":"Bahr","year":"1985","unstructured":"Bahr C von, Spina E, Birgensson C, Ericsson \u00d6, Henthorn T, Sj\u00f6qvist F (1985) Inhibition of desmethylimipramine 2-hydroxylation by drugs in human liver microsomes. Biochem Pharmacol 34:2501\u20132505","journal-title":"Biochem Pharmacol"},{"key":"0576_CR11","first-page":"206","volume":"7","author":"Ben\u00c3\u00adtez","year":"1989","unstructured":"Ben\u00edtez J, Pi\u00f1as B, Garc\u00eda MA, Mart\u00ednez C, LLerena A, Cobaleda J (1989) Debrisoquine oxidation phenotype in psychiatric patients. Psychopharmacol Ser 7:206\u2013210","journal-title":"Psychopharmacol Ser"},{"key":"0576_CR12","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/BF00626371","volume":"41","author":"Spina","year":"1991","unstructured":"Spina E, Martinez C, Caputti AP, Cobaleda J, Pi\u00f1as B, Carrillo JA, Ben\u00edtez J (1991) Debrisoquine oxidation phenotype during neuroleptic monotherapy. Eur J Clin Pharmacol 41:467\u2013470","journal-title":"Eur J Clin Pharmacol"},{"key":"0576_CR13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00007691-199202000-00001","volume":"14","author":"Baumann","year":"1992","unstructured":"Baumann P, Meyer JW, Amey M, Baettig D, Bryois C, Jonzier-Perey M, Koeb L, Monney C, Woggon B (1992) Dextromethorphan and mephenytoin phenotyping of patients treated with thioridazine or amitriptyline. Ther Drug Monit 14:1\u20138","journal-title":"Ther Drug Monit"},{"key":"0576_CR14","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1097\/00007691-200112000-00004","volume":"14","author":"LLerena","year":"2001","unstructured":"LLerena A, Berecz R, Rubia A de la, Fern\u00e1ndez-Salguero P, Dorado P (2001) Effect of thioridazine dosage on the debrisoquine hydroxylation phenotype in psychiatric patients with different CYP2D6 genotypes. Ther Drug Monit 14:616\u2013620","journal-title":"Ther Drug Monit"},{"key":"0576_CR15","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/00007691-199508000-00003","volume":"17","author":"Yasui","year":"1995","unstructured":"Yasui N, Otani K, Kaneko S, Ohkubo T, Osanai T, Ishida M, Mihara K, Kondo T, Sugawara K, Fukushima Y (1995) Inhibition of trazodone metabolism by thioridazine in humans. Ther Drug Monit 17:333\u2013335","journal-title":"Ther Drug Monit"},{"key":"0576_CR16","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1097\/00007691-199612000-00018","volume":"18","author":"Maynard","year":"1996","unstructured":"Maynard GL, Soni P (1996) Thioridazine interferences with imipramine metabolism and measurement. Ther Drug Monit 18:729\u2013731","journal-title":"Ther Drug Monit"},{"key":"0576_CR17","doi-asserted-by":"crossref","unstructured":"Stormer E, Brockmoller J, Roots I, Schmider J (2000) Cytochrome P-450 enzymes and FMO3 contribute to the disposition of the antipsychotic drug perazine in vitro. Psychopharmacology (Berl) 151:312\u2013320","DOI":"10.1007\/s002130000489"},{"key":"0576_CR18","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1521-0391.1996.tb00303.x","volume":"5","author":"Lavin","year":"1996","unstructured":"Lavin MR, Siris SG, Mason SE (1996) What is the clinical importance of cigarette smoking in schizophrenia? Am J Addict 5:189\u2013208","journal-title":"Am J Addict"},{"key":"0576_CR19","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1176\/ajp.149.9.1189","volume":"149","author":"Goff","year":"1992","unstructured":"Goff DC, Henderson DC, Amico E (1992) Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects. Am J Psychiatry 149:1189\u20131194","journal-title":"Am J Psychiatry"},{"key":"0576_CR20","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S0920-9964(01)00327-9","volume":"58","author":"LLerena","year":"2002","unstructured":"LLerena A, Rubia A de la, Pe\u00f1as-LLed\u00f3 E, De Leon J (2002) Schizophrenia and smoking in Spanish psychiatric patients. Schizophr Res 58:323\u2013327","journal-title":"Schizophr Res"},{"key":"0576_CR21","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/BF00174062","volume":"90","author":"Jann","year":"1986","unstructured":"Jann MW, Saklad SR, Ereshefsky L, Richards AL, Harrington CA, Davis CM (1986) Effects of smoking on haloperidol and reduced haloperidol plasma concentrations and reduced haloperidol clearance. Psychopharmacology 90:468\u2013470","journal-title":"Psychopharmacology"},{"key":"0576_CR22","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/0006-3223(85)90063-0","volume":"20","author":"Ereshefsky","year":"1985","unstructured":"Ereshefsky L, Jann MW, Saklad SR, Davis CM, Richards AL, Burch NR (1985) Effects of smoking on fluphenazine clearance in psychiatric inpatients. Biol Psychiatry 20:329\u2013332","journal-title":"Biol Psychiatry"},{"key":"0576_CR23","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/00004714-199302000-00006","volume":"13","author":"Perry","year":"1993","unstructured":"Perry PJ, Miller DD, Arndt SV, Smith DA, Holman TL (1993) Haloperidol dosing requirements: the contribution of smoking and nonlinear pharmacokinetics. J Clin Psychopharmacol 13:46\u201351","journal-title":"J Clin Psychopharmacol"},{"key":"0576_CR24","first-page":"1265","volume":"19","author":"Vinarova","year":"1984","unstructured":"Vinarova E, Vinar O, Kalvach Z (1984) Smokers need higher doses of neuroleptic drugs. Biol Psychiatry 19:1265\u20131268","journal-title":"Biol Psychiatry"},{"key":"0576_CR25","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/clpt.1988.115","volume":"44","author":"Ben\u00c3\u00adtez","year":"1988","unstructured":"Ben\u00edtez J, LLerena A, Cobaleda J (1988) Debrisoquine oxidation polymorphism in a Spanish population. Clin Pharmacol Ther 44:74\u201377","journal-title":"Clin Pharmacol Ther"},{"key":"0576_CR26","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/00008571-199706000-00004","volume":"7","author":"Marez","year":"1997","unstructured":"Marez D, Legrand M, Sabbagh N, Guidice JM, Spire C, Lafitte JJ, Meyer UA, Broly F (1997) Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 7:193\u2013202","journal-title":"Pharmacogenetics"},{"key":"0576_CR27","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1097\/01213011-199912000-00002","volume":"9","author":"Gaedigk","year":"1999","unstructured":"Gaedigk A, Gotschall RR, Forbes NS, Simon SD, Kearns GL, Leeder JS (1999) Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data. Pharmacogenetics 9:669\u2013682","journal-title":"Pharmacogenetics"},{"key":"0576_CR28","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/clinchem\/46.8.1072","volume":"8","author":"Hersberger","year":"2000","unstructured":"Hersberger M, Marti-Jaun J, Rentsch K, Hanseler E (2000) Rapid detection of the CYP2D6*3, CYP2D6*4, and CYP2D6*6 alleles by tetra-primer PCR and of the CYP2D6*5 allele by multiplex long PCR. Clin Chem 8:1072\u20131077","journal-title":"Clin Chem"},{"key":"0576_CR29","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0378-1119(98)00567-8","volume":"226","author":"Lundqvist","year":"1999","unstructured":"Lundqvist E, Johansson I, Ingelman-Sundberg M (1999) Genetic mechanisms for duplication and multiduplication of the human CYP2D6 gene and methods for detection of duplicated CYP2D6 genes. Gene 226:327\u2013338","journal-title":"Gene"},{"key":"0576_CR30","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1006\/bbrc.1999.0540","volume":"258","author":"Yasar","year":"1999","unstructured":"Yasar \u00dc, Eliasson E, Dahl ML, Johansson I, Ingelman-Sundberg M, Sj\u00f6qvist F (1999) Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. Biochem Biophys Res Commun 254:628\u2013631. Erratum in: Biochem Biophys Res Commun 258:227","journal-title":"Biochem Biophys Res Commun"},{"key":"0576_CR31","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1097\/00007691-200008000-00006","volume":"22","author":"LLerena","year":"2000","unstructured":"LLerena A, Berecz R, Rubia A de la, Norberto MJ, Ben\u00edtez J (2000) Use of the mesoridazine\/thioridazine ratio as a marker for CYP2D6 enzyme activity. Ther Drug Monit 22:397\u2013401","journal-title":"Ther Drug Monit"},{"key":"0576_CR32","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s00213-002-1059-5","volume":"162","author":"Jaanson","year":"2002","unstructured":"Jaanson P, Marandi T, Kiivet RA, Vasar V, Vaan S, Svensson JO, Dahl ML (2002) Maintenance therapy with zuclopenthixol decanoate: associations between plasma concentrations, neurological side effects and CYP2D6 genotype. Psychopharmacology 162:67\u201373","journal-title":"Psychopharmacology"},{"key":"0576_CR33","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2165\/00003088-200241070-00001","volume":"41","author":"Dahl","year":"2002","unstructured":"Dahl ML (2002) Cytochrome P450 phenotyping\/genotyping in patients receiving antipsychotics: useful aid to prescribing? Clin Pharmacokinet 41:453\u2013470","journal-title":"Clin Pharmacokinet"},{"key":"0576_CR34","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1177\/026988110201600411","volume":"16","author":"LLerena","year":"2002","unstructured":"LLerena A, Berecz R, Rubia A de la, Dorado P (2002) QTc interval lengthening is related to CYP2D6 hydroxylation capacity and plasma concentration of thioridazine in patients. J Psychopharmacol 16:359\u2013362.","journal-title":"J Psychopharmacol"},{"key":"0576_CR35","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1097\/00004714-199912000-00002","volume":"19","author":"Carrillo","year":"1999","unstructured":"Carrillo JA, Ramos SI, Herraiz AG, LLerena A, Ag\u00fandez JAG, Berecz R, Duran M, Ben\u00edtez J (1999) Pharmacokinetic interaction of fluvoxamine and thioridazine in schizophrenic patients. J Clin Psychopharmacol 19:494\u2013499","journal-title":"J Clin Psychopharmacol"},{"key":"0576_CR36","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/00008571-199408000-00005","volume":"4","author":"Bock","year":"1994","unstructured":"Bock KW, Schrenk D, Forster A, Griese EU, Morike K, Brockmeier D, Eichelbaum M (1994) The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes. Pharmacogenetics 4:209\u2013218","journal-title":"Pharmacogenetics"},{"key":"0576_CR37","first-page":"102","volume":"Toxicol","author":"Dorado","year":"2001","unstructured":"Dorado P, Norberto M, Berecz R, Mart\u00ednez M, Rubia A de la, Yasar \u00dc, Dahl ML, LLerena A (2001) CYP2C9 genotype and diclofenac hydroxylation in a Spanish population. Pharmacol Toxicol (Suppl 1) 89:102","journal-title":"Pharmacol"},{"key":"0576_CR38","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1097\/00008571-200204000-00010","volume":"12","author":"Lee","year":"2002","unstructured":"Lee CR, Goldstein JA, Pieper JA (2002) Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 12:261\u2013263","journal-title":"Pharmacogenetics"},{"key":"0576_CR39","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/clpt.1993.197","volume":"54","author":"LLerena","year":"1993","unstructured":"LLerena A, Herraiz AG, Cobaleda J, Johansson I, Dahl ML (1993) Debrisoquine and mephenytoin hydroxylation phenotypes and CYP2D6 genotype in patients treated with neuroleptic and antidepressant agents. Clin Pharmacol Ther 54:606\u2013611","journal-title":"Clin Pharmacol Ther"},{"key":"0576_CR40","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S0022-3565(24)38082-6","volume":"288","author":"Drolet","year":"1999","unstructured":"Drolet B, Vincent F, Rail J, Chahine M, Deschenes D, Nadeau S, Khalifa M, Hamelin BA, Turgeon J (1999) Thioridazine lengthens repolarization of cardiac ventricular myocytes by blocking the delayed rectifier potassium current. J Pharmacol Exp Ther 288:1261\u20131268","journal-title":"J Pharmacol Exp Ther"},{"key":"0576_CR41","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/0041-008X(86)90398-4","volume":"86","author":"Hale","year":"1986","unstructured":"Hale PW Jr, Poklis A (1986) Cardiotoxicity of thioridazine and two stereoisomeric forms of thioridazine 5-sulfoxide in the isolated perfused rat heart. Toxicol Appl Pharmacol 86:44\u201355","journal-title":"Toxicol Appl Pharmacol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-003-0576-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-003-0576-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-003-0576-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-003-0576-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T12:23:18Z","timestamp":1749730998000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-003-0576-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,3,28]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2003,5]]}},"alternative-id":["0576"],"URL":"https:\/\/doi.org\/10.1007\/s00228-003-0576-4","relation":{},"ISSN":["0031-6970"],"issn-type":[{"type":"print","value":"0031-6970"}],"subject":[],"published":{"date-parts":[[2003,3,28]]}}}